IR-Crizotinib

IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM) . IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research[1].

Product Specifications

CAS Number

2387927-74-2

UNSPSC

12352005

Target

NF-κB

Type

Reference compound

Related Pathways

NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ir-crizotinib.html

Solubility

10 mM in DMSO

Smiles

NC(C(O[C@@H](C1=C(Cl)C=CC(F)=C1Cl)C)=C2)=NC=C2C3=CN(N=C3)C4CCN(C5=C(/C=C/C6=[N+](C)C(C=CC=C7)=C7C6(C)C)CCC/C5=C\C=C8C(C)(C)C(C=CC=C9)=C9N/8C)CC4.[I-]

Molecular Formula

C53H57Cl2FIN7O

Molecular Weight

1024.87

References & Citations

[1]Pflug KM, et al. Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression. Mol Pharm. 2023 Nov 8.